- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Catabasis Pharmaceuticals announces preliminary Phase 1 data for hypercholesterolaemia product candidate CAT-2054
4 June 2015 • Author: Victoria White
Catabasis Pharmaceuticals has announced preliminary Phase 1 clinical trial data for CAT-2054, the Company’s product candidate targeting the Sterol Regulatory Element-Binding Protein, or SREBP, pathway for the potential treatment of hypercholesterolaemia.
In January 2015, the Company initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. Preliminary data are available for the full range of doses tested in the single and multiple ascending dose portions of the Phase 1 trial. Catabasis expects that full results will be available in the third quarter of 2015.
In the single ascending dose portion of the Phase 1 clinical trial, 38 healthy volunteers were randomised to receive CAT-2054 in capsules at doses ranging from 50 mg to 1000 mg or placebo. When single doses of CAT-2054 were administered under fed and fasted conditions, CAT-2054 was well-tolerated and no serious adverse events (AEs) were reported. No safety signals were observed in laboratory vital sign or electrocardiogram results following CAT-2054 administration. The observed AEs occurring under fed and fasted conditions at doses up to 500 mg were similar for CAT-2054 and placebo. All reported AEs were mild.
Statistically significant decreases in median LDL-C levels of up to 20% were observed in the CAT-2054 study
In the ongoing multiple ascending dose portion of the Phase 1 trial, 40 healthy volunteers have been randomised to receive CAT-2054 in soft gelatin capsules at daily doses ranging from 100 mg to 750 mg or placebo for 14 days. In these subjects, CAT-2054 was well-tolerated and no serious AEs were reported. No safety signals were observed in laboratory vital signs or electrocardiogram results following CAT-2054 administration and all subjects completed dosing. All reported AEs were mild.
Lipid biomarkers also were measured in the healthy volunteers enrolled in the Phase 1 trial. Decreases in LDL-C were observed at the end of the 14-day dosing period at doses of 500 and 750 mg. Decreases in median LDL-C levels of up to 20% were observed at day 21 which were statistically significant compared to baseline for all dose levels.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics